Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 601-608

  Mattison, Ryan J ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukaemia; Allogeneic hematopoietic cell transplantation; Autologous; Philadelphia chromosome

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CLINICAL TRIAL; HUMAN; IMMUNOPHENOTYPING; MORBIDITY; PATIENT CARE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; SKULL IRRADIATION; TREATMENT OUTCOME; ADULT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; REMISSION; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 74049096749     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833156eb     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
3. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation In the therapy of acute lymphoblastic leukemia In adults: an evidence-based review. Biol Blood Marrow Transplant 2006; 12:1-30. (Pubitemid 43034095)
4. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation In first complete remission, and an autologous transplantation Is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827-1833.
5. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 2007; 109:944-950. (Pubitemid 46220637)
6. Storb R, Bryant JI, Buckner CD, et al. Allogeneic marrow grafting for acute lymphoblastic leukemia: leukemic relapse. Transplant Proc 1973; 5:923926.
7. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versushost disease in human recipients of allogenelc-marrow grafts. N Engl J Med 1979;300:1068-1073. (Pubitemid 9198740)
8. Flere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11:1990-2001.
9. Thlebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Onool Clin North Am 2000; 14:1353-1366; x.
10. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment In adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22:4075-4086. (Pubitemid 41185176)
11. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment In adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multioenter LALA-94 trial. Blood 2002; 100: 2357-2366.
12. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation In adult acute lymphoblastic leukemia In first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994; 12:2580-2587.
13. Cornelissen JJ, van der Holt B, Verhoef GE, et al. Myeloablative allogeneic versus autologous stem cell transplantation In adult patients with acute lymphoblastic leukemia In first remission: a prospective sibling donor versus no-donor comparison. Blood 2009; 113:1375-1382.
14. Larson R, Dodge R, Bloomfield C, Schiffer C. Treatment of biologically determined subsets of acute lymphoblastic leukemia In adults: cancer and leukemia group B studies. In: Buchner T, Hiddemann W, Wormann B, editors. Acute leukemias Vl: prognostic factors and treatment strategies. Berlin: Springer-Verlag; 1997. pp. 677-686.
15. Gokbuget N, Raff R, Brugge-Mann M, et al. Rlsk/MRD adapted GMALL trials In adult ALL. Ann Hematol 2004; 83 (Suppl 1):S129S131.
16. Takeuohl J, KyoT, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by Intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSGALL93 study. Leukemia 2002; 16:1259-1266.
17. Hunauit M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104:3028-3037.
18. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pedlatric-based protocol ALL-96. J Clin Oncol 2008; 26:1843-1849.
19. Bassan R, Spinelli O, Oldanl E, et al. Improved risk classification for risk- specific therapy based on the molecular study of minimal residual disease (MRD) In adult acute lymphoblastic leukemia (ALL). Blood 2009; 113:4153-4162.
20. Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation In relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Onool 2009; 27:377-384.
21. Yanada M, Sugiura I, Takeuohl J, et al. Prospective monitoring of BCR-ABL1 transcript levels In patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinlb-combined chemotherapy. Br J Haematol 2008; 143:503-510.
22. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification In adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116-1123. (Pubitemid 43156313)
23. Messerer D, Neiss A, Aydemlr U, et al. How can disease-free survival of adult ALL patients with or without transplants be compared? Onkologie 1991; 14:53-55.
24. Ribera JM, Oriol A, Bethenoourt C, et al. Comparison of Intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremlssion treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90:1346-1356. (Pubitemid 41503650)
25. Gupta V, Yi QL, Brandwein J, et al. The role of allogeneic bone marrow transplantation In adult patients below the age of 55 years with acute lymphoblastic leukemia In first complete remission: a donor vs. no donor comparison. Bone Marrow Transplant 2004; 33:397-404. (Pubitemid 38313088)
26. Larson R. Allogeneic hematopoietic cell transplantation for adults with ALL. Bone Marrow Transplant 2008; 42 (Suppl 1):S1B-S24.
27. Slrohi B, Powles R, Treleaven J, et al. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia In first remission: single-center experience of 100 patients. Bone Marrow Transplant 2008; 42:105-112.
28. Rowe JM, Buck G, Moorman AV, et al. Standard consolidation/maintenance chemotherapy is consistently superior to a single autologous transplant for adult patients with acute lymphoblastic leukemia: results of the international ALL trial (MRC UKALL XII/ECOG E2993). ASH Annual Meeting Abstracts 2008; 112:3314.
29. Huguet F, Leguay T, Raffoux E, et al. Pedlatric-lnspired therapy In adults with • Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911-918.
30. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25:813-819. (Pubitemid 350002881)
31. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremlssion therapy Improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106:2657-2663. (Pubitemid 43911835)
32. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646-1654.
33. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paedlatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48:254-261. (Pubitemid 46238513)
34. Usvasalo A, Raty R, Knuutlla S, et al. Acute lymphoblastic leukemia In adolescents and young adults in Finland. Haematologica 2008; 93:1161-1168.
35. Stein A, Forman SJ. Allogeneic transplantation for ALL In adults. Bone Marrow Transplant 2008; 41:439-446.
36. Shimon A, Rand A, Hardan I, et al. Allogeneic hematopoietic stem-cell transplantation In adult acute lymphoblastic leukemia: better outcome In transplantation during first complete remission and with myeloablatlve conditioning. ASH Annual Meeting Abstracts 2008; 112:3295.
37. Stein A, Palmer J, O'Donnell M, et al. Reduced-intensity allogeneic peripheral blood stem cell transplantation for high-risk acute lymphoblastic leukemia: a potential therapeutic approach for high risk ALL patients not eligible for full Intensity transplantation. ASH Annual Meeting Abstracts 2008; 112: 4321.
38. Mohty M, Labopln M, Tabrizzl R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93:303-306.
39. Arnold R, Beelen D, Bornhaeuser M, et al. Stem cell transplantation In elderly patients with acute lymphoblastic leukemia (ALL) In first complete remission (CR1). ASH Annual Meeting Abstracts 2008; 112:1966.
40. Bachanova V, Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant 2008; 41:455-464.
41. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576-4583.
42. Bishop MR, Logan BR, Gandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008; 41:635-642.
43. Kumar P, Defor TE, Brunstein C, et al. Allogeneic hematopoietic stem cell transplantation In adult acute lymphocytic leukemia: Impact of donor source on survival. Biol Blood Marrow Transplant 2008; 14:1394-1400.
44. Atsuta Y, Suzuki R, Nagamura-lnoue T, et al. Disease-specific analyses of • unrelated cord blood transplantation compared with unrelated bone marrow transplantation In adult patients with acute leukemia. Blood 2009; 113: 1631-1638.
45. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia confirms superiority of allogeneic transplant over chemotherapy in the prelmatinlb era: Results from the International ALL trial MRC UKALLXII/ECOG2993. Blood 2009; 113:4489-4496.
46. Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase Inhibitors. Biol Blood Marrow Transplant 2008; 14:949-958.
47. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosomepositive acute lymphocytic leukemia with hyper-CVAD and imatlnib mesylate. Blood 2004; 103:4396-4407. (Pubitemid 38745962)
48. Vlgnetti M, Fazi P, Cimlno G, et al. Imatinib plus steroids Induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109:3676-3678. (Pubitemid 46641715)
49. Lee S, Kim YJ, Chung NG, et al. The extent of minimal residual disease reduction after the first 4-week imatinlb therapy determines outcome of allogeneic stem cell transplantation In adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009; 115:561-570.
50. Wetzler M, Stock W, Owzar K, et al. Sequential imatinlb and chemotherapy yield reverse-transoriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections In Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL): preliminary results of CALGB 10001. ASCO Annual Meeting Abstracts. J Clin Oncol 2006; 24:6549.
51. Burke MJ, Trotz B, Luo X, et al. Allo-hematopoietlc cell transplantation for Ph chromosome-positive ALL: Impact of imatlnib on relapse and survival. Bone Marrow Transplant 2009; 43:107-113.
52. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatlnib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109:2791-2793.
53. Foa R, Vitale A, Guarinl A, et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients: final results of the GIMEMA LAL1205 study. ASH Annual Meeting Abstracts. Blood 2008; 112 [abstr 305].